Repeated Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma.
Journal
Practical radiation oncology
ISSN: 1879-8519
Titre abrégé: Pract Radiat Oncol
Pays: United States
ID NLM: 101558279
Informations de publication
Date de publication:
Historique:
received:
12
03
2020
revised:
30
07
2020
accepted:
04
08
2020
pubmed:
14
8
2020
medline:
20
8
2021
entrez:
14
8
2020
Statut:
ppublish
Résumé
In clinical practice, whether cirrhotic livers in patients with hepatocellular carcinoma (HCC) can withstand repeated stereotactic body radiation therapy (SBRT) remains unclear. This study aimed to evaluate the outcomes and toxicities in these patients. This retrospective study included patients with HCC who were treated with SBRT at least twice between January 2012 and June 2019. Local control and overall survival rates were calculated. Liver function before and after irradiation was evaluated using the Child-Pugh score and modified albumin-bilirubin grade. All toxicities were assessed using the Common Terminology Criteria for Adverse Events (version 4.0). Fifty-two patients underwent 136 courses (148 lesions) of SBRT, which was mostly performed for out-of-field tumors but 3 in-field recurrences. The median follow-up duration from the first SBRT was 52.6 months (range, 15.7-89.3 months). The median gross tumor volume was 4.6 cm Repeated SBRT is feasible and produces minimal toxicity in patients with HCC and Child-Pugh scores of ≤7 and a low normal liver dose.
Identifiants
pubmed: 32791232
pii: S1879-8500(20)30205-8
doi: 10.1016/j.prro.2020.08.002
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
44-52Informations de copyright
Copyright © 2020 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.